Graphite Bio, Inc. stock is down -1.26% since 30 days ago. The next earnings date is Dec 12, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 November’s closed higher than October. In the last 1 Unusual Options Trades, there were 1 PUT.
Graphite Bio, Inc. engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression. GPH201 is a product candidate for the treatment of X-linked severe combined immunodeficiency syndrome.